Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus
Insider buying, institutional financing and early clinical data shape NeOnc’s progress toward potential brain cancer treatments.
Rhea-AI Summary
NeOnc Technologies Holdings (NTHI) CEO Amir F. Heshmatpour purchased 37,000 additional common shares on September 11, 2026, after a recently announced $15 million institutional financing.
The Form 4 filing shows a weighted-average purchase price of $3.6654 per share, or about $135,620, continuing his pattern of insider buying. The $15 million financing with healthcare-focused institutional investors, announced September 9, was priced at $4.20 per common share and accompanying warrant, covering about 3.57 million shares or equivalents plus five-year warrants for another 3.57 million shares at a $4.20 exercise price. Net proceeds are intended for working capital, general corporate purposes and redemption of Series A convertible preferred stock.
NeOnc is advancing brain cancer candidates NEO100 and NEO212 under a patented platform licensed from the University of Southern California, with patent protection reported through 2038 and early-stage clinical data guiding its FDA discussions.
Positive
- CEO insider purchase of 37,000 shares for approximately $135,620 on September 11, 2026
- $15 million institutional financing at $4.20 per share and accompanying warrant
- Financing covers about 3.57 million shares or equivalents plus warrants for another 3.57 million shares
- NEO100 Phase 2a six-month progression-free survival 48.9% vs 20% historical benchmark in 24 patients
- NEO100 median overall survival of 26.09 months in recurrent/progressive high-grade IDH1-mutant glioma
- NEO212 Phase 1 dose escalation completed with 610 mg selected as recommended Phase 2 dose
- Patented NEO platform licensed from USC with reported patent protection extending up to 2038
Negative
- Equity financing involves issuance of about 3.57 million new shares or equivalents plus warrants for another 3.57 million shares
- NEO100 data from a small, single-arm, open-label Phase 2a study without a randomized control group
- Both NEO100 and NEO212 remain investigational and require further clinical evidence and regulatory review before any approval
News Explained
The priced financing could expand the share base, but the release does not establish that the transaction has closed.
The $15 million financing is described as announced and priced rather than closed; if its disclosed shares or warrants are issued or exercised, the share base can expand and existing holders’ percentage ownership can fall.
A pre-funded warrant is sold near the full share price with a nominal exercise price and converts to shares when exercised; here, that makes the reported share equivalents potential future shares, while the separate warrants are described as rights to purchase shares.
As of
Sources and calculations
- Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus (2026-09-15)
- Dilution (2026-07-17)
- Pre-funded warrant (2026-07-17)
- NeOnc Technologies Holdings second-quarter 2026 fundamentals (2026Q2)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,973,420 / ($4,765,181 / 91) = 37.7 days
Details
Market Reaction – NTHI
Following this news, NTHI has declined 6.61%, reflecting a notable negative market reaction. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.53. Trading volume is above average at 1.8x the average, suggesting increased trading activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Insider purchase
- 37,000 shares at $3.6654 per share
- CEO purchase on September 11, 2026
- Financing size
- $15 million
- Healthcare-focused institutional financing
- Offering price
- $4.20 per common share and accompanying warrant
- Institutional financing
- Shares or equivalents
- Approximately 3.57 million
- Financing coverage
- Warrant shares
- Approximately 3.57 million shares
- Five-year warrants exercisable at $4.20
- Six-month progression-free survival
- 48.9%
- Phase 2a study versus 20% prespecified historical benchmark
- Median overall survival
- 26.09 months
- Phase 2a study in recurrent or progressive high-grade IDH1-mutant glioma
- Study enrollment
- 24 patients
- NEO100 Phase 2a study
Historical Context
-
CEO purchased 37,000 shares while NEO100 advanced toward a regulatory discussion
-
Company priced a $15 million offering involving shares and accompanying warrants
-
NEO100 reported six-month progression-free survival above its prespecified benchmark
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
form 4 regulatory
pre-funded warrants financial
phase 2a medical
type b meeting regulatory
blood-brain barrier medical
single-arm medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, Sept. 15, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) -- The Chief Executive Officer of NeOnc Technologies Holdings (NASDAQ:NTHI), Amir F. Heshmatpour has purchased another 37,000 shares of the company’s common stock, adding to his investment following NeOnc’s announcement of a
A September 14 Form 4 shows that Heshmatpour acquired shares on September 11 at a weighted-average price of
The institutional financing, announced September 9, was priced at
The combination of continued insider buying and institutional backing is tyipically an expression of investor determination, in this case in support of NeOnc’s effort to beat brain cancer. Heshmatpour is increasing his personal financial commitment as the company works to advance novel therapies built on its patented NEO technology platform.
That platform addresses a central challenge in treating brain tumors: delivering therapeutic agents to the brain. NeOnc has exclusively licensed a worldwide portfolio of issued patents and pending applications from the University of Southern California covering NEO100, NEO212 and related technologies. The company reports patent protections extending up to 2038.
NEO100 is a patented formulation of highly purified perillyl alcohol administered through the nose and designed to reach the brain along olfactory and trigeminal pathways. Patients in its Phase 2a study self-administered the investigational treatment at home.
On August 12, NeOnc reported positive topline results from that study in 24 patients with recurrent or progressive high-grade IDH1-mutant glioma. In the company’s reported analysis, six-month progression-free survival was
Behind those results are patients and families hoping for more time together. At the August 12 readout, NeOnc reported that one patient had remained progression-free for approximately 19 months and five of the 24 participants were still receiving treatment.
At-home dosing also raises an important quality-of-life possibility. Taking daily doses in familiar surroundings could reduce travel for treatment administration and ease some of the “white coat” anxiety associated with medical settings. For patients and caregivers, that may mean a less disruptive routine and more time around family, while maintaining necessary clinical follow-up. These are potential benefits of the delivery approach; NeOnc said quality-of-life analyses were still underway at the August 12 readout.
Following the readout, NeOnc said it intended to request a Type B meeting with the FDA to discuss a potential registrational development path. “Our priority now is to engage with the FDA and align on the most efficient path toward a registrational study,” Heshmatpour said in the company’s August 12 announcement.
NeOnc’s second lead candidate, NEO212, links perillyl alcohol with temozolomide in an oral molecule designed to improve delivery across the blood-brain barrier. In its June 16 update, the company reported completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose, providing another clinical program through which to evaluate the platform.
Both therapies remain investigational. The NEO100 results came from a small, single-arm, open-label study without a randomized control group, and further clinical evidence and regulatory review will be needed to establish whether the treatment can reach patients through an approved indication.
The pattern of progress is coming into focus; NeOnc’s reported clinical results, its CEO’s continued share purchases, and recent institutional backing are beginning to tell a consistent story. That alignment brings together important ingredients for potential success as the company works toward its next clinical and regulatory milestones.
About InvestorsTape.com
At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.
Contact
benh@investorstape.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.
General Disclaimer
InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.
This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities.
This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How were the terms of NeOnc’s recent $15 million financing structured?
The $15 million financing with healthcare-focused institutional investors was priced at $4.20 per common share and accompanying warrant. The offering covers about 3.57 million common shares or equivalents, plus warrants to purchase an additional 3.57 million shares. The warrants have an exercise price of $4.20 per share and a term of five years. Pre-funded warrants were available in place of common shares.
What does NeOnc plan to do with the net proceeds from the financing?
The company identified working capital, general corporate purposes and redemption of Series A convertible preferred stock as intended uses of the net proceeds from the $15 million offering.
What are the key design features and results of the NEO100 Phase 2a study?
NEO100 is a patented, highly purified perillyl alcohol formulation administered intranasally, designed to reach the brain via olfactory and trigeminal pathways. In the Phase 2a study, 24 patients with recurrent or progressive high-grade IDH1-mutant glioma self-administered treatment at home. Reported topline results included 48.9% six-month progression-free survival versus a prespecified 20% historical benchmark and 26.09 months median overall survival. At the August 12 readout, one patient had remained progression-free for about 19 months and five participants were still receiving treatment.
What potential quality-of-life advantages does NEO100’s delivery approach offer?
Patients in the NEO100 Phase 2a study self-administered daily doses at home, which may reduce treatment-related travel and lessen anxiety associated with clinical settings. The company highlighted that this could support a less disruptive daily routine for patients and caregivers while still allowing necessary clinical follow-up. These are described as potential benefits, and quality-of-life analyses were still underway at the time of the August 12 readout.
What are NeOnc’s stated next regulatory steps for NEO100?
Following the August 12 topline readout, the company said it intended to request a Type B meeting with the FDA to discuss a potential registrational development path for NEO100. The CEO stated that the priority is to engage with the FDA and align on the most efficient path toward a registrational study.
What is NEO212 and what progress has been reported so far?
NEO212 is an oral molecule that links perillyl alcohol with temozolomide, designed to improve delivery across the blood-brain barrier. In a June 16 update, the company reported completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose, providing another clinical program through which to evaluate the NEO platform. NEO212 remains investigational.
What intellectual property underpins NeOnc’s NEO platform?
NeOnc has exclusively licensed a worldwide portfolio of issued patents and pending applications from the University of Southern California covering NEO100, NEO212 and related technologies. The company reports that patent protections extend up to 2038.